Loading the company…
Loading the company…
In 2025, Irras reported engagement with 11 surgeons and other clinicians in the states MedaRep covers, worth $105K in consulting, speaking, meals and travel for its device products, the most in New York ($60K to 4). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: New York ($60K, 4 engaged), Pennsylvania ($31K, 2 engaged), Illinois ($6,968, 1 engaged), California ($3,840, 2 engaged), New Jersey ($3,037, 1 engaged).
In the last ten years FDA made 5 decisions for Irras (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2023 (1). The latest was on 2023-10-19.
| Family | Decisions on record |
|---|---|
| CSF shunts | 5 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2023-10-19 | 510(k) | K231664 | IRRAflow Active Fluid Exchange System (AFES) |
| 2022-12-08 | 510(k) | K222471 | IRRAflow Active Fluid Exchange System (AFES) |
| 2020-04-29 | 510(k) | K200807 | IRRAflow Catheter, IRRAflow Tube Set, IRRAflow Control Unit |
| 2019-11-15 | 510(k) | K192289 | IRRAflow Catheter, IRRAflow Tube Set, IRRAflow Control Unit |
| 2018-07-13 | 510(k) |
| K171880 |
| IRRAflow CNS System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Irras.